Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab

Triple-negative breast cancer (TNBC) is a biologically aggressive yet heterogeneous disease that disproportionately affects younger women and women of color compared to other breast cancer subtypes. The paucity of effective targeted therapies and the prevalence of chemotherapeutic resistance in high...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagegni, Nusayba A, Davis, Andrew A, Clifton, Katherine K, Ademuyiwa, Foluso O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064451/
https://www.ncbi.nlm.nih.gov/pubmed/35515356
http://dx.doi.org/10.2147/BCTT.S293597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064451/
https://www.ncbi.nlm.nih.gov/pubmed/35515356
http://dx.doi.org/10.2147/BCTT.S293597

Ejemplares similares